4 years ago

Microbiotica Secures £50 Million to Advance Microbiome-Based Therapeutics

  • UK-based healthtech company Microbiotica has raised £50 million in a Series B funding round to conduct clinical trials for its microbiome-based therapeutics

  • The funding round was led by Flerie Invest and Tencent, with additional investment from British Patient Capital, Cambridge Innovation Capital, IP Group, and Seventure Partners

  • Microbiotica will use the funding to advance clinical trials for two of its lead products, one for immuno-oncology and another for ulcerative colitis.

      • ProblemHealthcare

      "Many people suffer from diseases like cancer and inflammatory bowel disease, and current treatments are not always effective. "

      Solution

      "Microbiotica is developing personalized medicines based on the human microbiome, using AI to analyze datasets and identify therapeutic targets. They are currently focusing on cancer immunotherapy and inflammatory bowel disease, with the goal of creating treatments that are more effective and personalized for each patient."

      Covered on